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Abstract: Llama derived single domain antibodies (sdAb), the recombinantly expressed 
variable heavy domains from the unique heavy-chain only antibodies of camelids, were 
isolated from a library derived from llamas immunized with a commercial abrin toxoid 
preparation. Abrin is a potent toxin similar to ricin in structure, sequence and mechanism 
of action. The selected sdAb were evaluated for their ability to bind to commercial abrin as 
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well as abrax (a recombinant abrin A-chain), purified abrin fractions, Abrus agglutinin  
(a protein related to abrin but with lower toxicity), ricin, and unrelated proteins. Isolated 
sdAb were also evaluated for their ability to refold after heat denaturation and ability to be 
used in sandwich assays as both capture and reporter elements. The best binders were 
specific for the Abrus agglutinin, showing minimal binding to purified abrin fractions or 
unrelated proteins. These binders had sub nM affinities and regained most of their 
secondary structure after heating to 95 °C.  They functioned well in sandwich assays. 
Through gel analysis and the behavior of anti-abrin monoclonal antibodies, we determined 
that the commercial toxoid preparation used for the original immunizations contained a 
high percentage of Abrus agglutinin, explaining the selection of Abrus agglutinin binders.  
Used in conjunction with anti-abrin monoclonal and polyclonal antibodies, these reagents 
can fill a role to discriminate between the highly toxic abrin and the related, but much less 
toxic, Abrus agglutinin and distinguish between different crude preparations. 
Keywords: abrin; single domain antibody; reversible refolding 
 
1. Introduction  
Abrin, an extremely toxic protein isolated from Abrus precatorius, also known as the rosary pea 
plant, is a type 2 ribosomal inactivating protein (RIP).  Type 2 RIPs, like abrin and ricin, are 
characterized by having two subunits: an A-chain that inhibits protein synthesis by catalyzing the 
deadenylation of 28S rRNA [1], and a lectin B-chain that facilitates the uptake of the toxin into the  
cell [2,3]. The A and B subunits are joined by a single disulfide bond. Abrin and ricin are very similar 
in both structure and mode of action [4]. They share 40% identity between their A chains, including 
the enzymatic active site and 60% homology between the B chains [5,6]. Although the lethality of both 
ricin and abrin depends on the route of administration and the species challenged [7], abrin has been 
reported to be more lethal than ricin [8,9]. Abrin has the potential to be used as a toxic adulterant or as 
a component in a weapon of mass destruction, making the development of methods to detect and 
neutralize it important. 
Abrin exists as  several variants that can be separated by chromatography into three fractions:  
abrin I, II, and III [10].  These fractions show differences in their toxicity and ability to inhibit   
protein synthesis [11], however, the variants have been determined to be immunologically 
indistinguishable [12]. Abrin fractions I and III have essentially identical A chains, but differing B 
chains [13]. The abrin commercially available for research is sold as a mixture of the abrin fractions I, 
II, and III. In addition to the abrin fractions, the rosary pea plant contains a less toxic component 
termed  Abrus  agglutinin which shares about 80% homology to abrin, but is several orders of 
magnitude less toxic [14]. Unlike abrin, the Abrus agglutinin consists of a tetramer of two A and two B 
subunits  [14,15].  Notwithstanding these differences, most anti-abrin antibodies fail to distinguish 
between the abrin fractions and Abrus agglutinin proteins [12]. 
While conventional antibodies towards abrin, both polyclonal and monoclonal, have been utilized 
successfully in detection schemes  [8,16–21], there is interest in the development of recombinant Toxins 2011, 3                         
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ligands. Both DNA aptamers and conventional antibody fragments (single chain antibodies; scFv) that 
bind abrin have been described [18,22]. The aptamers were able to detect abrin at concentrations as 
low as 1 nM (~64 ng/mL) in an assay using a molecular light switching reagent which changed 
luminescence when the aptamer bound target. Addition of BSA or ricin also caused changes in the 
luminescence when using several of the developed aptamers, indicating that specificity could be a 
problem with the reagents and assay format [22]. Human scFv specific for abrin were selected from a 
naïve scFv phage displayed library. Selected binders were converted to a Fab format and had affinities 
of ~50–100 nM enabling detection of abrin to 35 and 75 ng/mL with minimal cross-reactivity towards 
ricin [18]. 
Single domain antibodies (sdAb) are the recombinant variable heavy domains from the heavy chain 
only antibodies found in camelids and sharks [23,24].  Unlike conventional antibodies, and their 
recombinant binding domains such as scFv, many sdAb are able to refold and bind antigen after heat 
or chemical denaturation [25,26]. SdAb have been developed towards a wide variety of targets and in 
addition to their stability [27], they have been shown to have high affinity and specificity, equivalent to 
conventional antibodies and their derivatives [28–30]. 
In an effort to develop high affinity, specific, and thermal stable recognition reagents, we isolated 
abrin binding elements from immune libraries of llama-derived sdAb displayed on phage. We panned 
the library against a commercial abrin preparation as well as abrin fractions I, II, and III. Selected 
sdAb were characterized by their ability to bind abrin, its variants, and the Abrus agglutinin as well  
as their ability to refold after heat denaturation. The isolated sdAb with the best affinities were found 
to recognize commercial abrin and the Abrus  agglutinin but not abrin fractions I, II, or III.  We  
also isolated binders towards abrin fraction I. Herein we detail the evaluation and characterization of 
these binders. 
2. Materials and Methods  
2.1. Reagents 
Commercial abrin, commercial abrin toxoid, and staphylococcal enterotoxin B (SEB) were purchased 
from Toxin Technology, Inc. (Sarasota, Fl). According to the product data sheet, the abrin toxoid had 
been prepared using a glutaraldehyde method.  Abrin fractions I, II, and III as well as the abrin 
agglutinin were supplied by the FDA as previously reported [10]. Ricin, ricin A chain, ricin B chain, 
and  Ricinus communis  Agglutinin (RCA120) were from Vector (Burlingame, CA).  Anti-abrin 
monoclonal antibodies (mAbs) 18E11 and 5F6 were provided by Tetracore, Inc. (Rockville, MD). 
Immunizations of two llamas were performed by Triple J Farms (Bellingham, WA).  PhycoLink
® 
Streptavidin-R-Phycoerythrin PJ31S (SA-PE) was purchased from Prozyme (San Leandro, CA).  
Anti-histidine tag-Phycoerythrin was obtained from Columbia Biosciences Corp. (Columbia, MD). 
Phosphate buffered saline (PBS), Tween 20, and bovine serum albumin (BSA) were obtained from 
Sigma-Aldrich (St. Louis, MO).  The  anti-M13 antibody was purchased from GE Healthcare 
(Piscataway, NJ). Enzymes for PCR and cloning were obtained from Invitrogen Corp. (Carlsbad, Ca) 
and New England Biolabs (Ipswich, MA). Toxins 2011, 3                         
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2.2. Abrax 
Abrax is an abrin A chain sequence recombinantly expressed in Escherichia coli which has been 
modified to include the mutations described for the ricin A chain vaccine [31]. Abrax was expressed 
from a pET28a in E. coli using autoinduction media. A single colony from the overnight growth was 
used to inoculate 10 mL  of Overnight Express Instant TB Autoinduction media (Novagen) with 
30 μg/mL kanamycin. The culture was grown to log phase in a shaking incubator at 37 °C. The culture 
was then scaled up to one liter and incubated for 20 h at 37 °C in a shaking incubator. The cell paste 
was harvested by centrifugation and frozen. The cell pellet was thawed and resuspended in 30 mL of 
His Tag binding buffer (20 mM Sodium Phosphate, 500 mM NaCl, 20 mM Imidazole, pH 8) to which 
300 μL of HALT EDTA free protease inhibitor cocktail (Fisher Scientific PI78415) was added. The 
cells were mechanically ruptured by two passages of the slurry through a French Pressure Cell Press at 
40,000 PSI. The crude extract was clarified by centrifugation at 100,00× g and the soluble phase was 
loaded onto a pre-packed 1 mL Ni Sepharose column (GE Life Sciences) and abrax was step eluted 
into 20 mM Sodium Phosphate, 500 mM NaCl, 500 mM Imidazole, pH 8. Peak Fractions were pooled 
and buffer exchanged into PBS. 
2.3. Library Construction and Selection  
Two llamas underwent a series of 9 immunizations with commercial abrin toxoid; the amount of 
antigen per immunization was increased from 10 μg on days 0 and 7 up to 100 μg per injection on days 
42, 56, and 84 of the protocol. On day 98, blood was collected from the immunized animals.  
White blood cells were isolated from 100 mL of llama blood and RNA was isolated using the 
QIAamp blood mini kit (Qiagen, Valencia, CA).  RNA was used in an oligo-dT primed reverse 
transcription reaction.  PCR amplification of the heavy domain antibodies was performed using 
flanking primers as described previously [32,33]. The resulting sdAb genes were digested, gel purified, 
and cloned into phage display vector pecan21 [33,34].  
Selections for abrin binders were carried out essentially as previously described [33]. During the 
course of this work, the library was panned against the commercial abrin, abrax, and purified abrin 
fractions. The only alteration to the previously published panning protocol was that during the third 
round selections, wash buffer was left in the wells for 30 min between the PBST (PBS with 0.05% 
Tween-20) and PBS wash sets in an effort to eliminate lower affinity binders.  
Monoclonal phage enzyme linked immunosorbent assays (ELISAs) were performed after the first, 
second and third rounds of panning to identify individual positive clones.  Luminex was used to 
confirm positive clones [35]. Selected positive clones were sequenced to identify unique sdAb genes, 
and sequences were aligned using the Multalin program [36].  Representative sdAb clones were 
subcloned from the phage display sdAb-fusion vector to a soluble sdAb expression vector, and 
transformed into E. coli  Rosetta (Novagen, Madison, WI) for protein production as described 
previously [33,37]. Toxins 2011, 3                         
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2.4. Luminex Assays 
Luminex (Austin, TX) carboxylated microspheres were cross-linked to a variety of proteins using 
the two-step carbodiimide coupling protocol provided by the manufacturer.  Direct binding and 
sandwich assays were performed as previously described [37–39]. The signal for Luminex experiments 
is reported as the median fluorescence intensity (MFI) of at least 100 separate microspheres. 
2.5. Surface Plasmon Resonance (SPR)  
The SPR kinetic measurements were performed using the ProteON XPR36 (Bio-Rad Laboratories, 
Hercules, CA). GLC chips coated with the various toxins (commercial abrin, abrax, Abrus agglutinin, 
and abrin fractions I, II, and III), were used to measure the kinetics of anti-abrin sdAb binding. The 
toxins were immobilized to the chips, each at 5 µg/mL in acetate buffer (pH 5.0), according to the 
standard EDC coupling chemistry provided by the manufacturer. Association and dissociation between 
the sdAb (injected at six concentrations ranging from 0 to 30 nM) and the immobilized toxins were 
monitored for 180 and 600 s, respectively, using a flow rate of 50 µL/min. When evaluating mAbs, 
concentrations ranging from 0 to 30  nM were used. The chip was regenerated using 50 mM   
glycince–HCl (pH 2.0) for 36 s, prior to any additional testing. All experiments were performed at  
25 °C. The data were analyzed using the ProteON Manager
TM 2.1 software. The binding constants were 
determined using the software’s Langmuir model after subtracting the zero antibody concentration 
column and interspot correction. A bivalent fit was used to analyze the data from the mAbs. 
2.6. Circular Dichroism (CD) 
The melting points of selected sdAb were measured by circular dichroism using a Jasco J-815 CD 
spectropolarimeter equipped with a PTC-423S single position peltier temperature control system. 
Samples (~25 µg/mL) were prepared by dialysis versus 5 mM sodium borate pH 8.0, or by dilution. 
Measurements were made in a 10 mm pathlength quartz cuvette with a stir bar. Melting point data 
were acquired at a single wavelength between 202 and 210 nm, at a temperature rate of 5 °C/min over 
the range of 25 °C to 95 °C. 
3. Results and Discussion 
A library of phage displaying sdAb, derived from two llamas immunized with a commercial abrin 
toxoid, was constructed. After performing two rounds of selection using commercial abrin, 48 clones 
each from the first and second rounds of panning were evaluated by monoclonal phage ELISA to 
evaluate their ability to bind to the commercial abrin preparations. About 55% of the clones selected 
after the first round of panning and 70% of the clones selected after the second round were positive 
with a signal-to-noise ratio of at least 3. Forty of the binding phages from the first and second rounds, 
along with three non-binders, were examined by Luminex to assess the affinity and specificity to the 
commercial  abrin, abrax (recombinant abrin A-chain), ricin, ricin-A chain, and ricin B-chain 
(Figure S1). Only one phage showed binding to the abrax coated microspheres. Of the positives, 23 
that were strongly positive by both ELISA and Luminex were sent for DNA sequencing. Sequences fit 
into six unique families (typified by Abr1, Abr2, Abr4, Abr5, Abr6, and Abr11; Figure S2). Several Toxins 2011, 3                         
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clones that were positive by ELISA did not show appreciable signal when tested by Luminex phage 
direct binding assays and were not sequenced or evaluated further. 
Representatives from each of the six unique sequence families were mobilized to the protein 
expression vector and soluble protein was produced. Direct binding experiments were performed using 
the Luminex to determine the specificity of the clones (Figure 1). Clones Abr1, Abr2 and Abr 5 
appeared to be the most specific  for commercial abrin and commercial  abrin toxoid,  showing no 
binding to ricin, the ricin A or B- chains, RCA120, or unrelated proteins SEB and BSA. The Abr 1 
clone showed the highest signal with abrax, and was the only one of the six binding families that 
recognized the abrax. Clones Abr4 and Abr11 displayed moderate cross-reactivity with ricin B chain at 
high sdAb concentrations, while Abr6 showed strong cross-reactivity to ricin B chain.  
Figure 1. Luminex direct binding, representatives of the first six sequence families isolated 
through panning two rounds on commercial abrin. The sdAb were examined for binding to 
commercial abrin (abrin), abrax, and commercial abrin toxoid (abrin-td) as well as the 
related toxin ricin, ricin a chain, ricin b chain, and RCA120,  and unrelated proteins 
staphylococcal enterotoxin B (SEB), and bovine serum albumin (BSA). 
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Only one abrax binding family was identified containing only one member, Abr1.  To isolate 
additional sdAb that recognized abrax, two rounds of selection were performed using the abrax target. 
All 32 binding sequences from these selections fell into the same sequence family as Abr1. These 
results suggest that there are not many members of the library with high affinity for the abrin A chain 
or that other A chain binders make important contacts with the amino acids that have been changed in 
the abrax construct. Camelid sdAb have been shown to bind to enzyme active sites [40], accessing 
epitopes that are not available to conventional antibodies.  
A third round of selection on the commercial abrin employed a longer washing steps in an effort to 
further down select binders with high affinity; two additional sequence families, N5 and N12 were 
identified (Figure S2). These binders were evaluated by Luminex direct binding assays, along with two Toxins 2011, 3                         
 
 
1411 
anti-abrin monoclonal antibodies (mAbs),  to determine their specificity.  Clone  N12  showed  high 
specificity  while  N5 cross-reacted  with ricin at the highest concentration examined (Figure  2). 
Sandwich assays demonstrated that the Abr 2 and N5 bound to different epitopes on the toxin 
(Figure S3) and could potentially be used as a captor tracer pair. 
Figure 2. Luminex direct binding, representatives of the two sequence families isolated 
after panning three rounds on commercial abrin and two anti-abrin mAbs. The sdAb and 
mAbs were examined for binding to commercial abrin (abrin), abrax, and commercial abrin 
toxoid (abrin-td) as well as the related toxin ricin, ricin a chain, ricin b chain, and rca120. 
Note the difference in the scale of the Y axis between the mAbs and sdAb. 
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One advantage of sdAb over conventional antibodies is their ability to refold after heat 
denaturation.  Circular dichroism analysis of Abr2, N5, and N12 confirmed that all three clones 
regained at least 75% of their secondary structure after heating to 95 °C (Figure 3). While most sdAb 
examined are able to refold and to bind antigen after denaturation, it is important to determine the 
ability of each clone to refold as some sdAb do not regain structure and function after heating [41]. Toxins 2011, 3                         
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Figure 3. Circular dichroism on the three sdAb that showed high affinity and specificity 
to the commercial abrin toxin.  Each sdAb was monitored through one heating and 
cooling cycle. 
Abr2 N12 N5
 
The association and dissociation rate constants for commercial abrin, abrax, abrin fraction I, and 
Abrus agglutinin are listed in Tables 1 and 2 (representative SPR data in Figure S4). The sdAb that had 
been identified as the best binders, Abr2, N5, and N12 were found to have sub nM affinities toward 
commercial abrin, the antigen that they were selected against, and Abrus agglutinin. However, Abr2, 
N5, and N12 did not bind abrax or the purified abrin fractions (data for abrin fractions II and III not 
shown). Abr4 and Abr6, which displayed cross-reactivity with ricin B-chain, did not bind abrax but 
bound commercial abrin, Abrus agglutinin, and all three abrin fractions with greatest affinity for abrin 
fraction I (data not shown for fractions II and III). Although the three abrin fractions had been reported 
to be immunologically indistinguishable [12], there are reports of anti-ricin antibodies that react with 
only one of the analogous 3 ricin fractions [42]. Thus, the preferential recognition of fraction I by Abr4 
and Abr6 may represent inclusion in the epitope of sequence differences between the fractions that 
were not observed previously.  
Table 1. Binding to commercial abrin and abrax. 
Binder 
Commercial Abrin   Abrax 
on, 1/Ms  off, 1/s  Kd, M 
a  on, 1/Ms  off, 1/s  Kd, M 
a 
mAb 5F6   1.5 × 10
5  6.1 × 10
−4  4.0 × 10
−9  NB  NB  NB 
mAb 18E11  2.0 × 10
5  1.9 × 10
−2  9.3 × 10
−8  1.5 × 10
5  3.4 × 10
2  2.2 × 10
−7 
Abr1  NB  NB  NB  1.8 × 10
5  4.79 × 10
5  2.64 × 10
−10 
Abr2  2.2 × 10
6  3.2 × 10
−5  1.5 × 10
−11  NB  NB  NB 
Abr4  4.2 × 10
5  2.7 × 10
−4  6.5 × 10
−10  NB  NB  NB 
N5  1.6 × 10
5  3.1 × 10
−5  1.9 × 10
−10  NB  NB  NB 
N12  3.7 × 10
6  4.5 × 10
−6  1.2 × 10
−12  NB  NB  NB 
Abr6  8.3 × 10
4  1.1 × 10
−4  1.3 × 10
−9  NB  NB  NB 
3E  3.3 × 10
5  2.4 × 10
−4  7.4 × 10
−10  NB  NB  NB 
10C  8.6 × 10
5  9.7 × 10
−4  1.1 × 10
−9  NB  NB  NB 
NB = no binding observed; 
a Kd values are calculated from kd/ka; Binding constants for mAbs 
were determined using a bivalent model while those for sdAb were done with a Langmuir model. Toxins 2011, 3                         
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Table 2. Binding to abrin fraction I and abrin agglutinin. 
Binder 
Abrin frac I   Abrus Agglutinin 
on, 1/Ms  off, 1/s  Kd, M 
a  on, 1/Ms  off, 1/s  Kd, M 
a 
mAb 5F6   1.6 × 10
5  12.1 × 10
−4  1.3 × 10
−9  1.5 × 10
5  6.3 × 10
−4  4.3 × 10
−9 
mAb 18E11  1.2 × 10
5  1.1 × 10
−2  8.5 × 10
−8  1.8 × 10
5  1.6 × 10
−2  9.0 × 10
−8 
Abr1  NB  NB  NB  NB  NB  NB 
Abr2  NB  NB  NB  1.1 × 10
6  1.6 × 10
−5  1.4 × 10
−11 
Abr4  1.5 × 10
5  1.6 × 10
−4  1.1 × 10
−9  5.1 × 10
5  4.9 × 10
−4  9.5 × 10
−10 
N5  NB  NB  NB  1.8 × 10
5  5.3 × 10
−5  2.9 × 10
−10 
N12  NB  NB  NB  1.6 × 10
6  4.2 × 10
−6  2.6 × 10
−12 
Abr6  4.0 × 10
4  2.1 × 10
−4  5.2 × 10
−9  9.1 × 10
4  2.6 × 10
−5  2.9 × 10
−10 
3E  1.2 × 10
5  1.6 × 10
−4  1.3 × 10
−9  5.3 × 10
5  4.2 × 10
−4  7.8 × 10
−10 
10C  3.2 × 10
5  6.5 × 10
−4  2.0 × 10
−9  1.2 × 10
6  8.1 × 10
−4  6.6 × 10
−10 
NB = no binding observed; 
a Kd values are calculated from kd/ka; Binding constants for mAbs 
were determined using a bivalent model while those for sdAb were done with a Langmuir model. 
While SPR experiments showed  Abr1 to have a high affinity for abrax, Abr1 did not bind 
commercial abrin, abrin fraction I, or Abrus agglutinin, indicating that it may recognize an epitope that 
is partially in the interface of the A and B chains and only accessible when the abrin A chain is 
separate. Thus, sdAb Abr1 may be useful to discriminate purified abrin A chain from the whole toxin. 
By itself the abrin’s A chain is not a toxic threat, but there may be circumstances in which it is 
important to differentiate the whole toxin from its component chains, especially when engineered 
immuno-toxins are real possibilities.  
Having ascertained that initially selected sdAb bound best to either the agglutinin or to abrax, 
selections of the constructed phage library were carried out on the abrin fractions in the hope of 
isolating high affinity sdAb specific for the toxin.  Two rounds of selection were performed and 
24 clones that were positive by monoclonal phage ELISA were sent for sequencing; all isolated 
binders were from the existing families of Abr1, Abr4 and Abr6. Two binders, 3E and 10C, in the 
Abr4 family were chosen for further evaluation and shown to bind to the abrin I fraction (Figure 4; 
Table 2). These representatives would be expected to perform equivalent to Abr4 in sandwich assays, 
which had not shown particularly promising results. 
In addition to the anti-abrin sdAb, two anti-abrin mAbs were evaluated. Tight binding was observed 
between mAb 5F6 and commercial abrin (Kd of 4 nM) while mAb 18E11 displayed poor binding  
(Kd of 93 nM). In contrast, no binding was observed between mAb 5F6 and abrax while mAb 18E11 
displayed a Kd of 0.2 μM. Both mAb 5F6 and mAb 18E11 bound fraction I and Abrus agglutinin with 
Kd values <0.1 μM. When comparing these values to the affinity constants of the sdAb, it is important 
to realize that a bivalent model was used to calculate binding constants for the mAbs. As each mAb 
has two antigen binding sites, its effective binding to the abrin benefits from an avidity component, 
that increases its apparent affinity. Toxins 2011, 3                         
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Figure 4. Luminex direct binding, representatives of two clones isolated after panning on 
the abrin fractions. Binding data is shown for commercial abrin (abrin), the abrin fractions 
(Frac I, Frac II, and Frac III), the commercial abrin toxoid (abrin td), the Abrus agglutinin 
(Abrus Agg), ricin b chain (RB), ricin a chain (RA), Abrax, ricin, and RCA120. 
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Sandwich assays were performed on the Luminex instrument for the detection of commercial abrin, 
abrin fractions and the Abrus  agglutinin using the sdAb, mAbs, and polyclonal llama anti-abrin 
(Figure 5). The data were plotted as the ratio of the signal at a given abrin concentration to that of the 
signal when no abrin was added. A ratio of at least 5 was chosen to indicate a positive response. 
Commercial abrin was readily detected using sdAb as either the capture or tracer antibody. The best 
limit of detection, 1.6 ng/mL, was achieved when the N12 sdAb was paired with a llama anti-abrin 
polyclonal as the tracer antibody. When mAb 18E11 was used as a capture reagent in combination 
with the llama anti-abrin polyclonal tracer, a comparable LOD value of 1.6 ng/mL was achieved with a 
mixture of abrin fractions I, II and III. Although the Abr4 family of sdAb has a good affinity towards 
the purified abrin fractions according to the SPR measurements, none of the sdAb were able to detect 
the abrin fractions when used as a tracer in combination with the mAbs, sdAb N12, or llama anti-abrin 
capture (Figure S5). The inability of the Abr4 family sdAb to function well in sandwich assays may be 
due to the presence of reactive amines at or near the combining site for this family of sdAb. Since the 
addition of biotin is amine directed, it would then have the potential to interfere with binding. The 
Abr4 family has multiple  Arginines within  the hyper variable regions (2 within complementarity 
determining region (CDR) 2, and 2 within CDR 3), and several in framework regions that are not 
present in the other families of abrin-binding sdAb; biotinylation at these sites could potentially 
interfere with abrin binding.  It is interesting to note that the Abr4 family sdAb were not able to 
function as capture reagents in Luminex assays; since the EDC coupling employed is also amine 
directed, they may immobilize in an orientation that does not permit target binding. The N12 sdAb 
capture  and the Abr2, N5, and N12 sdAb tracers, however, were useful in the detection of the 
agglutinin, with the best pairs showing signals at concentrations as low as  1.6 ng/mL  (Figure 5; 
Figure S5).  Toxins 2011, 3                         
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Figure 5.  Sandwich assay using the Luminex  for commercial abrin (panel A), abrin 
fractions I II and III (panel B), and Abrus agglutinin (panel C) with a sdAb and monoclonal 
captures paired with a llama polyclonal tracer. Data is reported as the ratio of signal over 
background, with a value of 5 considered positive. 
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The material used for the original immunizations was the commercial abrin toxoid, a toxoid version 
of commercial abrin. Commercial abrin is a mixture of fractions I, II, and III, and Abrus agglutinin. 
Native and denaturing gels of the commercial abrin displayed bands almost identical to the Abrus 
agglutinin but considerably different from the purified fractions (Figure S6), indicating that Abrus 
agglutinin is present at a considerably greater concentration than the toxin variants. Therefore, it was 
not surprising that Abrus agglutinin binders were isolated. However, the lack of sdAb specific for abrin 
was a disappointment. Possibly the phage display repertoire of sdAb were dominated by the most 
immunogenic component present in the immunization, reiterating the importance of antigen   
purity [43]. Nonetheless, in combination with an antibody that recognizes abrin, such as the llama 
polyclonal anti-abrin, an assay that discriminates between abrin and the Abrus  agglutinin can be 
developed using the sdAb and mAbs. Such an assay enables different sources and preparations of abrin 
to be distinguished and can serve as a key component in determining attribution in criminal cases. 
4. Summary  
Specific and high affinity sdAb recognition elements for Abrus agglutinin have been isolated. By 
combining these sdAb with either llama polyclonal anti-abrin antibodies or commercially available 
mAbs specific for abrin, it is possible to quantitatively determine the abrin and Abrus  agglutinin 
composition of samples. Since commercial and crude home preparations routinely contain Abrus 
agglutinin, the material’s composition may serve as a fingerprint for attribution and threat agent Toxins 2011, 3                         
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forensics. Isolation of high affinity sdAb specific for abrin fractions I, II, and III, remains an important 
goal that may require sdAb libraries developed after immunization with either toxoids derived from the 
purified abrin fractions or active toxins/subunits. In addition to detection, a goal of sdAb development 
has been to isolate reagents able to inhibit toxin activity. SdAb have been described that recognized 
ricin A chain and inhibit ricin activity in cell culture [38]. There have also been reports of sdAb that 
neutralize botulinum neurotoxins [44–47]. Recently an abrin A chain binding monoclonal antibody 
was shown to completely inhibit abrin activity both in cell culture and in mice [48], showing that 
antibodies can be isolated that inhibit abrin activity. 
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